Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists

被引:34
作者
Allison, Brett D. [1 ]
Phuong, Victor K. [1 ]
McAtee, Laura C. [1 ]
Rosen, Mark [1 ]
Morton, Magda [1 ]
Prendergast, Clodagh [1 ]
Barrett, Terry [1 ]
Lagaud, Guy [1 ]
Freedman, Jamie [1 ]
Li, na Li [1 ]
Wu, Xiaodong [1 ]
Venkatesan, Hariharan [1 ]
Pippel, Marna [1 ]
Woods, Craig [1 ]
Rizzolio, Michele C. [1 ]
Hack, Michael [1 ]
Hoey, Kenway [1 ]
Deng, Xiaohu [1 ]
King, Christopher [1 ]
Shankley, Nigel P. [1 ]
Rabinowitz, Michael H. [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA
关键词
D O I
10.1021/jm060590x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-5-chlorobenzoyl]- piperidine (1;CCK-2R, pK(I)) 6.4). Preliminary exploration of the structure- activity relationships around the anthranilic ring and the amide and sulfonamide moieties led to a nearly 50-fold improvement of receptor affinity and showed a greater than 1000-fold selectivity over the related cholecystokinin-1 receptor. Pharmacokinetic evaluation led to the identification of 4-[4-iodo-2-[(5-quinoxalinylsulfonyl) amino]benzoyl]-morpholine, 26d, a compound that demonstrates promising pharmacokinetic properties in the rat and dog with respect to plasma clearance and oral bioavailability and is a potent inhibitor in vivo of pentagastrin-stimulated acid secretion in the rat when dosed orally.
引用
收藏
页码:6371 / 6390
页数:20
相关论文
共 42 条